Pure Global
NCT06124885

Real-time Early Detection of Nephrotoxicity by Urinary Biomarker Analysis With SeroFlow Technology

Real-time Early Detection of Nephrotoxicity by Accurate and Faster Urinary Biomarker Analysis With SeroFlow Technology (RenaFAST Study)
National University Hospital, Singapore·ClinicalTrials.gov·diagnostic testRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acute Kidney Injury
Drug/Device/Intervention
AKI risk screening using RenaFAST POCT test kits
Study type
Interventional
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
National University Hospital, Singapore
Location
Singapore, Singapore
Timeline & enrollment
Phase
N/A
Start date
Nov 01, 2023
End date
Dec 01, 2024
Enrollment
150 participants
Primary outcome

Presence of an Acute kidney injury (AKI) event

Summary

The study aims to perform real-time validation of the RenaFAST kit (a point-of-care test kit
 that quantifies three urinary proteins) in predicting acute kidney injury(AKI) among patients
 prescribed drug therapies of nephrotoxic potential. Based on the type and duration of drug
 therapy, a maximum of 5 time-point urine samples will be collected from consenting patients
 and a real-time biomarker analysis will be conducted using the RenaFAST kits.

ICD-10 classifications
Injury of kidneyAcute renal failureAcute renal failure, unspecifiedOther acute renal failureAcute renal failure with tubular necrosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06124885
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06124885 through Pure Global AI's free database. This phase not specified trial is sponsored by National University Hospital, Singapore and is currently Recruiting. The study focuses on Acute Kidney Injury. Target enrollment is 150 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.